Source link : https://www.newshealth.biz/health-news/promising-results-with-epcoritamab-monotherapy-in-relapsed-refractory-cll/
SAN DIEGO — Single-agent epcoritamab (Epkinly) achieved encouraging response rates in patients with heavily-pretreated chronic lymphocytic leukemia (CLL), according to early results from a phase I trial. The overall response rate (ORR) was 67% among 21 of 23 evaluable patients treated with the CD3 x CD20 bispecific antibody in an expansion cohort of the EPCORE […]
Author : News Health
Publish date : 2024-12-08 22:15:53
Copyright for syndicated content belongs to the linked Source.
inHealth